What is NDC 0187-0004?

0187-0004 is the product NDC for Siliq (brodalumab), Brodalumab 210 mg/1 injection, listed with the FDA by Bausch Health US LLC. It has 3 package NDCs, shown above in 10- and 11-digit form.

Bausch Health US LLC, NDC labeler code 0187. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Siliq?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Siliq NDC 0187-0004 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0187-0004Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00187-0004Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0187-0004-02	00187000402	2 SYRINGE in 1 CARTON (0187-0004-02) / 1 INJECTION in 1 SYRINGE (0187-0004-00)Marketed from Feb 15, 2017
0187-0004-03	00187000403	2 INJECTION in 1 CARTON (0187-0004-03)Marketed from Jun 1, 2026 · Sample package
0187-0004-04	00187000404	1 INJECTION in 1 SYRINGE (0187-0004-04)Marketed from Jun 1, 2026 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Siliq
Generic name (nonproprietary): brodalumab
Active ingredients: Brodalumab — 210 mg/1
Dosage form: Injection
Route: Subcutaneous
Labeler: Bausch Health US LLCNDC labeler code 0187
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761032
Marketing start: Feb 15, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Monoclonal (Chemical structure)Interleukin 17 Receptor A Antagonists (Mechanism)
Identifiers: Product ID 0187-0004_5fbd9beb-42b9-4360-8363-71f8f0c5a52eSPL ID 5fbd9beb-42b9-4360-8363-71f8f0c5a52eSPL set ID 1a550c33-456a-4833-814e-8591aea7c688RxCUI 1872256, 1872261UNII 6ZA31Y954Z
Pharmacologic class: Interleukin-17 Receptor A Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400187000402 followed by a unit qualifier and the quantity

Package 00187-0004-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 28, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is a human interleukin-17 receptor A (IL-17RA) antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0187-0004

What is NDC 0187-0004?: 0187-0004 is the product NDC for Siliq (brodalumab), Brodalumab 210 mg/1 injection, listed with the FDA by Bausch Health US LLC. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Siliq (Brodalumab).
What is the active ingredient?: Brodalumab.
Who is the labeler?: Bausch Health US LLC, NDC labeler code 0187. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Siliq?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Siliq (Brodalumab) NDC 0187-0004